GlassScriptPhysician profile
David Glen Mchenry
NPI 1053494831
$18,366.17
in general payments reported to CMS, 2019-2025
77 companies · $2,974 in 2025
The $2,974 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,747 · 2020: $1,534 · 2021: $1,963 · 2022: $2,787 · 2023: $2,874 · 2024: $3,486 · 2025: $2,974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,334.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,240.73 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $1,107.81 | 2019-2025 | |
| Pfizer INC. | $957.59 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $933.21 | 2019-2025 | Nuplazid, Daybue |
| Abbvie INC. | $883.57 | 2021-2025 | |
| Genentech USA, INC. | $786.15 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Ucb, INC. | $689.84 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Sk Life Science, INC. | $682.00 | 2020-2025 | |
| Genzyme Corporation | $629.38 | 2019-2023 | |
| Argenx US, INC. | $627.95 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Biogen, INC. | $579.91 | 2021-2025 | Vumerity, Leqembi, Tysabri |
| Lilly USA, LLC | $569.19 | 2019-2025 | Kisunla, Reyvow, Emgality |
| Alexion Pharmaceuticals, INC. | $445.50 | 2021-2025 | Ultomiris, Soliris |
| Emd Serono, INC. | $416.25 | 2019-2025 | Mavenclad |
| Lundbeck LLC | $409.69 | 2019-2025 | Vyepti, Rexulti |
Show all 77 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $375.09 | 2023-2025 | Nuedexta, Rexulti |
| Neurocrine Biosciences, INC. | $372.03 | 2019-2025 | Ingrezza, Ongentys |
| Ani Pharmaceuticals, INC. | $357.06 | 2024-2025 | Purified Cortrophin Gel |
| Amgen INC. | $322.81 | 2021-2025 | Uplizna, Aimovig |
| Medtronic, INC. | $308.89 | 2021-2023 | Linq II |
| Sunovion Pharmaceuticals INC. | $304.46 | 2019-2022 | |
| Allergan, INC. | $293.90 | 2019-2022 | |
| Medtronic USA, INC. | $293.40 | 2019-2020 | |
| Eisai INC. | $292.94 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $266.29 | 2019-2025 | Zeposia, Eliquis |
| Acorda Therapeutics, INC | $244.85 | 2019-2023 | Inbrija |
| Catalyst Pharmaceuticals, INC. | $241.26 | 2023-2025 | Fycompa, Firdapse |
| Jazz Pharmaceuticals INC. | $225.54 | 2019-2025 | |
| Celgene Corporation | $217.12 | 2021-2023 | Zeposia |
| Tg Therapeutics, INC. | $203.09 | 2023-2025 | |
| Amylyx Pharmaceuticals, INC. | $184.58 | 2023-2024 | Relyvrio |
| Avanir Pharmaceuticals, INC. | $183.78 | 2019-2022 | |
| Livanova USA, INC. | $154.75 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Biohaven Pharmaceutical Holding Company LTD. | $152.74 | 2022 | |
| Ge Healthcare | $144.69 | 2019-2022 | |
| Microtransponder, INC. | $136.45 | 2024 | |
| Neurelis, INC. | $133.75 | 2020-2023 | Valtoco |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $114.94 | 2019-2025 | Hyqvia |
| Astrazeneca Pharmaceuticals LP | $110.24 | 2021-2025 | Wainua |
| Supernus Pharmaceuticals, INC. | $99.44 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $98.27 | 2023-2024 | Aptiom |
| Kyowa Kirin, INC. | $96.19 | 2019-2023 | Nourianz |
| Biohaven Pharmaceuticals, INC. | $93.09 | 2020-2021 | |
| Mdd US Operations, LLC | $89.88 | 2020-2023 | Gocovri, Xadago, Apokyn |
| Alnylam Pharmaceuticals INC. | $68.73 | 2024-2025 | Amvuttra, Givlaari |
| Greenwich Biosciences, INC. | $67.88 | 2021 | |
| Corium, LLC | $66.72 | 2022-2023 | Adlarity |
| Mallinckrodt Hospital Products INC. | $66.01 | 2023-2025 | Acthar |
| Impel Pharmaceuticals INC. | $62.44 | 2023 | Trudhesa |
| Janssen Pharmaceuticals, INC | $57.54 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $57.06 | 2019-2024 | Ongentys, Rytary |
| Sanofi-Aventis U.S. LLC | $56.68 | 2020-2021 | |
| Merz Pharmaceuticals, LLC | $54.18 | 2024-2025 | Xeomin |
| Vanda Pharmaceuticals INC. | $50.00 | 2024-2025 | Ponvory |
| Grifols USA, LLC | $49.59 | 2019 | |
| Novocure INC. | $48.97 | 2023 | Optune |
| Adamas Pharmaceuticals, INC. | $43.09 | 2019 | |
| Axsome Therapeutics, INC. | $42.59 | 2023-2024 | Sunosi |
| Horizon Therapeutics Plc | $42.27 | 2022-2023 | Uplizna |
| Akcea Therapeutics, INC. | $31.05 | 2019 | |
| Chiesi USA, INC. | $30.94 | 2019-2020 | |
| Csl Behring | $30.57 | 2022 | |
| Mallinckrodt Enterprises LLC | $29.58 | 2019 | |
| Arbor Pharmaceuticals, INC. | $24.65 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $20.46 | 2021 | |
| Xeris Pharmaceuticals, INC. | $20.40 | 2024 | Keveyis |
| Ceribell, INC. | $17.83 | 2025 | Pocket Eeg Device |
| Janssen Biotech, INC. | $17.09 | 2025 | |
| Mylan Specialty L.P. | $15.67 | 2022 | |
| Vertical Pharmaceuticals, LLC | $15.47 | 2019 | |
| Boston Scientific Corporation | $15.01 | 2025 | Wavewriter Alpha Prime 16 |
| Portola Pharmaceuticals, LLC | $14.55 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.54 | 2023 | Quviviq |
| Kedrion Biopharma, INC. | $14.31 | 2024 | Gammaked, Rhogam Ultra-Filtered Plus, Koate |
| Tanabe Pharma America, INC. | $13.55 | 2022 | |
| Assertio Therapeutics, INC. | $11.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mchenry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.